Recovery outcomes can vary widely depending on the primary substance involved, with factors such as the drug’s neurobiology, available treatments, and relapse patterns all influencing success rates. This page explores how success rates differ across alcohol, opioid, stimulant, and other substance use disorders—and why individualized, evidence-based approaches are key to improving recovery odds for each.
Not all addictions respond to treatment in the same way. The path to recovery—and the likelihood of sustained sobriety—depends heavily on the substance involved, how it affects the brain and body, and the types of treatment available. By understanding these variations, patients and families can set more realistic expectations and choose the most effective, evidence-based programs for their specific needs.
Before comparing outcomes by substance, it is critical to clarify what is meant by “success” in the field.
As the All In Solutions hub page “Rehab Success Rates” states, definitions of success vary widely: some measure “success” as complete abstinence, others as reduced use, improved quality of life, or improved mental-health/functional outcomes.
Important dimensions include:
Program completion (i.e., client remains in program through the planned discharge)
Sustained abstinence or significantly reduced substance use at follow-up
Improved co-occurring mental-health symptoms, social functioning, employment/housing stability
Engagement in continuing care (aftercare, peer support)
For example, All In Solutions’ 2024 Satisfaction & Completion Report shows high levels of client satisfaction across its network and meaningful reductions in anxiety and depression among participants.
When interpreting “success rates,” keep in mind: the measurement criteria, the length of follow-up, the treatment setting (inpatient vs outpatient), and individual client variability.
Typical 12-month abstinence ranges reported by studies are broad (roughly 20–50% depending on population, treatment intensity, and follow-up methods), but this widens when “success” includes reduced heavy drinking and improved quality of life. Large specialty programs that combine intensive treatment and strong continuing care sometimes report higher one-year abstinence figures.3, 4
The evidence base for alcohol includes effective pharmacotherapies (naltrexone, acamprosate, disulfiram), structured psychotherapies such as CBT, and robust community mutual-help resources (Alcoholics Anonymous and manualized Twelve-Step Facilitation). A major Cochrane-style meta-analysis and subsequent reviews found that AA/TSF interventions can yield equal or superior long-term continuous abstinence compared with many alternatives, and may reduce healthcare costs when implemented properly.5, 6
Practical implication: For people with AUD, the best outcomes typically come from combining medication (when indicated), evidence-based therapy, and long-term participation in recovery support (peer groups, continuing care). Programs that actively link patients to continuing care show higher 12-month success and quality-of-life measures.4, 7
OUD historically had among the worst relapse and overdose rates when treated without medications. The widespread adoption of Medication-Assisted Treatment (MAT) — methadone, buprenorphine, and extended-release naltrexone — has changed the prognosis. Large reviews and public-health analyses show that MAT reduces illicit opioid use, increases retention in care, and cuts overdose mortality risk by roughly half compared with untreated or non-MAT care.8,9,10
Outcome examples: patients on methadone or buprenorphine commonly demonstrate much higher one-year retention/abstinence from illicit opioids (often 50–60% or higher for engagement and no illicit use) than patients attempting abstinence without medication (often well below 20% in many studies). Longer-term follow-ups show sustained benefits when patients remain engaged in MAT.2, 11
Public-health note: MAT’s life-saving effect is substantial—studies tracked by NIH and federal agencies document 50–60% reductions in opioid overdose deaths among patients receiving methadone or buprenorphine. Yet MAT remains underutilized in many settings, and access barriers (prescribing limits, pharmacy availability) blunt its population impact. Improving access to MAT is one of the most effective ways to raise overall OUD success rates.8, 12
Unlike alcohol and opioids, there are currently no widely accepted, FDA-approved medications that reliably produce long-term abstinence for stimulant use disorders. As a result, success rates for sustained abstinence are generally lower and relapse is common. However, behavioral interventions—especially contingency management (CM) and cognitive behavioral therapy (CBT)—produce meaningful gains: CM produces some of the highest short-term abstinence rates for stimulants, and CBT supports relapse prevention and functional recovery.7, 13
Typical trial results show relatively low proportions achieving complete abstinence during study windows (single digits to low double digits), but a larger share achieve substantial, clinically meaningful reductions in use that reduce harms and improve mental-health outcomes. Recent meta-analyses and trial syntheses emphasize that even reductions in frequency/intensity of stimulant use translate to improved life functioning and health.7
Research outlook: Promising pharmacologic candidates and immunotherapy approaches are under investigation; success rates may improve if one or more effective medications emerge. In the meantime, enhancing access to Contingency Management (CM) and integrating stimulant-specific behavioral care into MAT programs for polysubstance users can boost outcomes. (See the “polysubstance” section below.)7
Cannabis, benzodiazepines, tobacco, and polysubstance presentations
Behavioral therapy (CBT, motivational interviewing) reliably helps many users reduce or quit; outcomes vary by severity and patient goals (abstinence vs reduced/problem use), but moderate success is common in clinical programs.
Successful withdrawal and long-term outcomes hinge on gradual tapering, treating underlying anxiety/insomnia, and avoiding abrupt discontinuation; relapse can occur if the root anxiety remains untreated.
High-quality pharmacotherapies (nicotine replacement, varenicline, bupropion) plus behavioral support yield some of the best quit rates across addictive substances—though multiple quit attempts are common.
Patients using multiple drugs (e.g., opioids + stimulants) typically have lower single-drug success rates unless treatment actively addresses all substances and co-occurring mental health disorders. Integrated, individualized care improves outcomes in polysubstance populations.
Residential/inpatient care tends to have higher program completion rates and stronger short-term abstinence vs standard outpatient—useful for stabilization, especially when patients face unstable home environments or severe withdrawal. National datasets (TEDS) and program outcome reports show substantially higher completion rates for residential levels of care relative to standard outpatient. However, long-term success often depends on aftercare and continuing support.1
Intensive Outpatient / Partial Hospitalization (IOP/PHP) provide more structure than weekly outpatient and often achieve retention and outcomes between residential and standard outpatient—particularly effective when incorporated as a step-down after residential care.
Length of treatment matters: multiple studies and treatment guidelines suggest greater benefits with treatment “dose” of at least ~90 days (or equivalent across a continuum of care), with continued engagement (aftercare, 12-step, medication maintenance) strongly associated with better 6–12 month outcomes. Early dropout is among the strongest predictors of poor long-term results.4, 7
The largest gains in long-term recovery occur when initial treatment is followed by continuing care—alumni programs, 12-step or mutual-help involvement, outpatient therapy boosters, medication maintenance, and case management for housing/employment. Programs with strong aftercare handoffs show superior 12-month outcomes.4, 7
How they fit into this landscape
All In Solutions’ internal outcomes report (2024) documents high program completion and strong symptom-improvement figures (e.g., completion rates and PHQ-9/GAD-7 improvements).
Those internal results compare favorably to national benchmarks such as SAMHSA’s TEDS and independent outcome research from major providers—suggesting that rigorous retention and integrated behavioral/medical care can push results above national averages.
For provider-level benchmarking, use national public datasets (TEDS) and major center outcome reports (e.g., Hazelden’s Butler Center reports) to place a program’s metrics into context.14, 1, 4
If you or a loved one is ready to seek treatment, our admissions team is available 24/7 to assist you through the process. Our admissions specialists will answer your questions about insurance and help you find the level of care that works best for you.
1 – https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018-TEDS-R.pdf
2 – https://nida.nih.gov/research-topics/medications-opioid-use-disorder
3 – https://www.hazeldenbettyford.org/about/treatment-success-rates
5 – https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012880.pub2/full
7 – https://pmc.ncbi.nlm.nih.gov/articles/PMC4510025/
9 – https://www.nejm.org/doi/full/10.1056/NEJMp1402780
10 – https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760032
11 – https://pmc.ncbi.nlm.nih.gov/articles/PMC4801718/
12 – https://time.com/6186319/buprenorphine-overdoses-pharmacy-drug-treatment/
13 – https://www.hazeldenbettyford.org/research-studies/addiction-research/recovery-management
14 – https://www.allinsolutions.com/alcohol-drug-rehab-success-rate-studies-and-statistics/
